BCBS Michigan saved $67 million and $80 million in 2024 and 2025, respectively, through biosimilar use, the insurer reported Feb. 17. The company began moving members from Humira and Stelara to ...

MedImpact Holdings, Inc. today announced the launch of an unbranded biosimilar to Humira® (adalimumab) priced at 95% below ...

High- and low-concentration interchangeable biosimilar will be available, estimated to save individual patients around $3,500 on average per year Biosimilar price will be about 85% lower than Humira ® ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

The use of biosimilars saved Blue Cross members and employee groups $67 million in 2024 and $80 million in 2025, according to a news release. The savings come amid a cost-cutting push at Blue Cross to ...

SPRINGFIELD, Mass. (WWLP) – Health New England announced Monday that it will shift coverage of the biologic drug Humira to more affordable FDA-approved biosimilars starting next month for members of ...

Biosimilars demonstrate comparable drug survival and safety with adalimumab among new users, but patients switching from Humira (the originator product) to biosimilars had a 35% higher discontinuation ...

Credit: Celltrion. Yuflyma, a tumor necrosis factor blocker, was approved in May 2023 as a biosimilar to Humira. Similar PK, efficacy, safety, and immunogenicity data were observed between the ...

The approval of the interchangeable designation was supported by data from a randomized, double-blind phase 4 trial (ClinicalTrials.gov Identifier: NCT05510063) that assessed the pharmacokinetics, ...